The legal landscape for abortion is undeniably murky. Since the rollback of federal abortion protection, states have been tasked with defining the boundaries of reproductive rights. More than a dozen states have near-total abortion…
Continue Reading
In other words, the fund appears to be at least 100 million euros.
“This is as far as I can go,” he demurred, declining to clarify whether the math was correct.
He explained that 70% of…
Almost three-quarters of all clinical trials are run by the same 5% of academic sites, according to Inato CEO Kourosh Davarpanah.
“This lack of patient access causes trial delays and costs to skyrocket, ultimately constraining…
FDA approval of Pfizer nasal spray migraine drug Zavzpret last week means a $475 million payday for Royalty Pharma. The payment stems from a financing deal Pfizer inherited when it acquired rights to the…
Continue Reading
New medications take too long to get into the hands of people who need them – a decade, on average. The leading cause of delays is finding patients for clinical trials, but it shouldn’t…
Continue Reading
Vaccine developer Vaxart contends its pill vaccinations against Covid-19 will be preferable to patients, and potentially more effective than currently available injections. But a different virus offers the biotech a clearer and faster path…
Continue Reading
Large Language Models (LLM) like ChatGPT have taken the world by storm, with everyone from researchers to tech enthusiasts excited about the almost limitless potential of these models. And yes, I’ll admit it that…
Continue Reading
Life sciences organizations have access to more data than ever before. When they leverage that existing data during their research and development (R&D) process, organizations can drive more efficient drug development.
Innovation and regulatory approval…
More than a decade after the Affordable Care Act was signed into law, U.S. healthcare costs continue to spiral at rates unseen in the rest of the developed world.
But while healthcare costs overall are…
Gene therapy for hemophilia A patients in the U.S. will have to wait. The FDA needs more time to review data from BioMarin Pharmaceuticals, and the agency told the company it won’t be able…
Continue Reading
